BackEnimmune corporation Overview

Enimmune corporation Long Term Debt

Enimmune corporation's long-term debt is $36M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$36.01M
↑ 30.24% YoYΔ $8.36M vs prior year quarter

Peer trimmed avg / median

Loading

Enimmune corporation Long Term Debt History

Loading

Enimmune corporation vs. peers: Long Term Debt Comparison

Loading

Enimmune corporation Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Enimmune corporation (6564.TWO) FAQ

The latest long-term debt for 6564.TWO is $36M as of June 2026. That compares with $28M in the prior-year period — up 30.2% year over year. Investors often review this figure alongside Enimmune corporation's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6564.TWO's long-term debt moved from $28M to $36M — a 30.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Enimmune corporation's operating scale or balance-sheet position.

A long-term debt figure of $36M for 6564.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6564.TWO's long-term debt ($36M), review year-over-year change from $28M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Enimmune corporation's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.